Looking for novel, effective and less toxic therapies for cervical cancer is of significant importance. In this study, we reported that HMQ-T-F2(F2) signifi- 
| INTRODUCTION
Cervical cancer is the fourth most common type of cancer and has the highest mortality rate among cancers in women. 1 The conserved Wnt/b-catenin signal transduction pathway is a critical pathway in several types of cancers, including cervical cancer, 2 and controls many biological processes. 3 Whether the Wnt/b-catenin pathway is activated or not depends on the stability of b-catenin in the cytoplasm. b-catenin is regulated by a degradation complex that consists of the scaffolding protein Axin, which recruits essential elements during this process, such as the tumour suppressor adenomatous polyposis coli gene product (APC), casein kinase 1 (CK1) and glycogen synthase kinase 3b (GSK3b).
Depending on the type and stage of cancer, treatments for cervical cancer include surgery, radiation therapy, chemotherapy and targeted therapy. Chemotherapy is often used to treat tumours that have spread or have reappeared after treatment. 4 Therefore, there is an urgent need for more effective and less toxic therapies that could be represented by molecular target-directed drugs. HMQ-T-F2
(F2)(1-(4-(2-aminoquina zolin-7-yl)phenyl)-3-(4-bromo-2-(trifluoromethoxy)phenyl)thiourea) ( Figure 1A ) is a novel biphenyl urea derivatives designed using dissection strategies in our laboratory. 5 In this study, we investigated the effect of HMQ-T-F2 on cervical tumour cell proliferation and explored in more depth HMQ-T-F2 as novel inhibitors of the Wnt/b-catenin signal pathway.
| MATERIALS AND METHODS

| Chemicals and cell lines
HMQ-T-F2 (purity > 98%) were synthesized in the Research and Engineering Center for Natural Medicine, Xi'an Jiaotong University.
ZR-75-30, MCF-7, SMMC-7721, Hep3B, Bel-7402, A549, A431, ECV304, LOVO, and human cervical cancer cell line HeLa, Ca Ski, SiHa and MS751 were obtained from Shanghai Institute of Cell Biology in the Chinese Academy of Sciences. Human normal cervical 
| Colony-forming assay
HeLa cells were seeded and treated with HMQ-T-F2 for 48 hours.
The colonies were stained with crystal violet and photographed.
| In vivo assay
Mice were injected with 2 9 10 6 HeLa cells. Mice were randomly assigned and respectively treated with vehicle (0.5% CMC-Na), HMQ-T-F2 (5 mg/kg every day by intragastric administration. Mice weight and tumour volume were monitored every other day. After 14 days, mice were euthanized, and the tumours weights were recorded. | 2957
were subjected to RT-PCR and western blotting. The transfected cells were used for cell proliferation assay.
| Statistical analysis
One-way analysis of variance (ANOVA) and further Tukey's multiple comparison test as well as independent-samples t test were used. A P value <.05 was considered statistically significant. *P < .05, **P < .01, ***P < .001 compared to control group, # P < .05, ### P < .001 compared to HMQ-T-F2-treated groups, &&& P < .001 compared to XAV939-treated groups. Data are expressed as means AE SEM.
| RESULTS AND DISCUSSION
Chemotherapy plays a vital role in treating cervical cancer that has spread or has relapsed after treatment. 6 Thus, searching for more effective and b-catenin target-directed drugs is an important issue in anti-cervical cancer drug development. In this study, we found that 
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